The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Coverage Launched on Co. in Alzheimer's Drug Space

Research Report
  ()
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Research Report
  ()
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

Biopharma Co. to Launch Two Clinical Trials This Year

Research Report
  ()
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

First Results From Biotech Co.'s Lymphoma Program Are Impressive

Research Report
  ()
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.

Analyst Says Avivagen Is a Strong Buy

Contributed Opinion
  ()
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.

Pilot Launch of VLN Cigarettes in Progress

Research Report
  ()
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.

Biotech Co. Advances COVID-19 Vaccines Toward Approval

Research Report
  ()
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.

Could a New Prescription Drug Treat This Common Ailment?

Research Report
  ()
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.

Senior Biotech Analyst's Top 3 Stocks

  ()
Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs.

Life Sciences Co. Expected to Attract Partners, Big Pharma

Research Report
  ()
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases.

Can We Make a Pill to End the Pandemic?

Contributed Opinion
  ()
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

Showing Results: 1 to 25 of 104 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts